Biogen to CMS: Reverse Aduhelm’s proposed coverage limits February 14, 2022 Auto Bot News 0 Biogen is urging CMS to reconsider a proposed guidance that would significantly limit coverage of its Alzheimer’s drug Aduhelm.
